AU2014240026B2 - Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders - Google Patents
Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders Download PDFInfo
- Publication number
- AU2014240026B2 AU2014240026B2 AU2014240026A AU2014240026A AU2014240026B2 AU 2014240026 B2 AU2014240026 B2 AU 2014240026B2 AU 2014240026 A AU2014240026 A AU 2014240026A AU 2014240026 A AU2014240026 A AU 2014240026A AU 2014240026 B2 AU2014240026 B2 AU 2014240026B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- cell
- pct
- cftr
- dbm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 *c(cccc1C=C2c3c[s]c(Nc(cc4)cc(C(F)(F)F)c4Cl)n3)c1OC2=O Chemical compound *c(cccc1C=C2c3c[s]c(Nc(cc4)cc(C(F)(F)F)c4Cl)n3)c1OC2=O 0.000 description 8
- UYOYELNMFMSHIM-UHFFFAOYSA-N CC(NC(Nc1cccc(C)c1OC)=S)=O Chemical compound CC(NC(Nc1cccc(C)c1OC)=S)=O UYOYELNMFMSHIM-UHFFFAOYSA-N 0.000 description 1
- NGMASWGAYXMFFT-UHFFFAOYSA-N CCCCCCCCCCOc1cccc(C=C2c3c[s]c(Nc4ccccc4OC)n3)c1OC2=O Chemical compound CCCCCCCCCCOc1cccc(C=C2c3c[s]c(Nc4ccccc4OC)n3)c1OC2=O NGMASWGAYXMFFT-UHFFFAOYSA-N 0.000 description 1
- TVGZBXCTMAXFGX-UHFFFAOYSA-N CCCOc(cc1)cc(Nc2nc(C3=Cc4cccc(Cl)c4OC3=O)c[s]2)c1OC Chemical compound CCCOc(cc1)cc(Nc2nc(C3=Cc4cccc(Cl)c4OC3=O)c[s]2)c1OC TVGZBXCTMAXFGX-UHFFFAOYSA-N 0.000 description 1
- REJYTGPJRHGGMM-UHFFFAOYSA-N CCOC(c1c[s]c(C2=Cc(cccc3Cl)c3OC2=O)n1)=O Chemical compound CCOC(c1c[s]c(C2=Cc(cccc3Cl)c3OC2=O)n1)=O REJYTGPJRHGGMM-UHFFFAOYSA-N 0.000 description 1
- FCVGOMWOHVBYNV-UHFFFAOYSA-N COC(c1cccc(C=C2c3c[s]c(Nc4ccccc4OC)n3)c1OC2=O)=O Chemical compound COC(c1cccc(C=C2c3c[s]c(Nc4ccccc4OC)n3)c1OC2=O)=O FCVGOMWOHVBYNV-UHFFFAOYSA-N 0.000 description 1
- YJTPSENFINOEBO-UHFFFAOYSA-N COc(cccc1)c1Nc1nc(C2=Cc(nc[o]3)c3OC2=O)c[s]1 Chemical compound COc(cccc1)c1Nc1nc(C2=Cc(nc[o]3)c3OC2=O)c[s]1 YJTPSENFINOEBO-UHFFFAOYSA-N 0.000 description 1
- IHLKDFZPUHOIHY-UHFFFAOYSA-N COc1ccccc1Nc1nc(C2=Cc(cccc3C(O)=O)c3OC2=O)c[s]1 Chemical compound COc1ccccc1Nc1nc(C2=Cc(cccc3C(O)=O)c3OC2=O)c[s]1 IHLKDFZPUHOIHY-UHFFFAOYSA-N 0.000 description 1
- XXSDNIBVHFSSPM-UHFFFAOYSA-N COc1ccccc1Nc1nc(C2=Cc(cccc3I)c3OC2=O)c[s]1 Chemical compound COc1ccccc1Nc1nc(C2=Cc(cccc3I)c3OC2=O)c[s]1 XXSDNIBVHFSSPM-UHFFFAOYSA-N 0.000 description 1
- CYISFPIBUYTIEM-UHFFFAOYSA-N COc1ccccc1Nc1nc(C2=Cc(cccc3OCc(c(Cl)c4)ccc4Cl)c3OC2=O)c[s]1 Chemical compound COc1ccccc1Nc1nc(C2=Cc(cccc3OCc(c(Cl)c4)ccc4Cl)c3OC2=O)c[s]1 CYISFPIBUYTIEM-UHFFFAOYSA-N 0.000 description 1
- KVDADEIZZCUQGV-UHFFFAOYSA-N COc1ccccc1Nc1nc(C2=Cc(cccc3OCc4cc(-c5ccccc5)ccc4)c3OC2=O)c[s]1 Chemical compound COc1ccccc1Nc1nc(C2=Cc(cccc3OCc4cc(-c5ccccc5)ccc4)c3OC2=O)c[s]1 KVDADEIZZCUQGV-UHFFFAOYSA-N 0.000 description 1
- HWSJTRXBXZFKRC-UHFFFAOYSA-N Cc(cc1)cc(Nc2nc(C3=Cc(cccc4Cl)c4OC3=O)c[s]2)c1OC Chemical compound Cc(cc1)cc(Nc2nc(C3=Cc(cccc4Cl)c4OC3=O)c[s]2)c1OC HWSJTRXBXZFKRC-UHFFFAOYSA-N 0.000 description 1
- DFCHYVWFVLCGCL-UHFFFAOYSA-N Cc(cccc1C=C2c3c[s]c(N(C)C)n3)c1OC2=O Chemical compound Cc(cccc1C=C2c3c[s]c(N(C)C)n3)c1OC2=O DFCHYVWFVLCGCL-UHFFFAOYSA-N 0.000 description 1
- FMLJHAHJVYPRAV-UHFFFAOYSA-N Cc(cccc1N)c1OC Chemical compound Cc(cccc1N)c1OC FMLJHAHJVYPRAV-UHFFFAOYSA-N 0.000 description 1
- NJSDEAUNYRISGB-UHFFFAOYSA-N Cc(cccc1Nc2nc(C3=Cc(cccc4Cl)c4OC3=O)c[s]2)c1OC Chemical compound Cc(cccc1Nc2nc(C3=Cc(cccc4Cl)c4OC3=O)c[s]2)c1OC NJSDEAUNYRISGB-UHFFFAOYSA-N 0.000 description 1
- OCSBJPCSPDPAQL-UHFFFAOYSA-N Cc(cccc1[N+]([O-])=O)c1OC Chemical compound Cc(cccc1[N+]([O-])=O)c1OC OCSBJPCSPDPAQL-UHFFFAOYSA-N 0.000 description 1
- DFCZDEVTKZMJSJ-UHFFFAOYSA-N Cc1cc(Nc2c[s]c(C3=Cc4cccc(Cl)c4OC3=O)n2)cc(C)c1 Chemical compound Cc1cc(Nc2c[s]c(C3=Cc4cccc(Cl)c4OC3=O)n2)cc(C)c1 DFCZDEVTKZMJSJ-UHFFFAOYSA-N 0.000 description 1
- DGHSHNVQRIOFRW-UHFFFAOYSA-N Cc1cc(Nc2cnc(C3=Cc(cccc4Cl)c4OC3=O)[s]2)cc(C)c1 Chemical compound Cc1cc(Nc2cnc(C3=Cc(cccc4Cl)c4OC3=O)[s]2)cc(C)c1 DGHSHNVQRIOFRW-UHFFFAOYSA-N 0.000 description 1
- LPKISSCFQPZFKW-UHFFFAOYSA-N Cc1cccc(NC(N)=S)c1OC Chemical compound Cc1cccc(NC(N)=S)c1OC LPKISSCFQPZFKW-UHFFFAOYSA-N 0.000 description 1
- LEAGPHZRDZNSCR-UHFFFAOYSA-N Cc1ncnc(C=C2c3c[s]c(Nc4ccccc4OC)n3)c1OC2=O Chemical compound Cc1ncnc(C=C2c3c[s]c(Nc4ccccc4OC)n3)c1OC2=O LEAGPHZRDZNSCR-UHFFFAOYSA-N 0.000 description 1
- VDNUYJDHCZENOB-UHFFFAOYSA-N Nc1nc(C2=Cc(cccc3Cl)c3OC2=O)c[s]1 Chemical compound Nc1nc(C2=Cc(cccc3Cl)c3OC2=O)c[s]1 VDNUYJDHCZENOB-UHFFFAOYSA-N 0.000 description 1
- CPEKAXYCDKETEN-UHFFFAOYSA-N O=C(c1ccccc1)N=C=S Chemical compound O=C(c1ccccc1)N=C=S CPEKAXYCDKETEN-UHFFFAOYSA-N 0.000 description 1
- VMIWIYSJAKYNIN-UHFFFAOYSA-N OC1Oc(c(Cl)ccc2)c2C=C1C(CBr)=O Chemical compound OC1Oc(c(Cl)ccc2)c2C=C1C(CBr)=O VMIWIYSJAKYNIN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361788353P | 2013-03-15 | 2013-03-15 | |
| US61/788,353 | 2013-03-15 | ||
| PCT/US2014/027079 WO2014152213A2 (en) | 2013-03-15 | 2014-03-14 | Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014240026A1 AU2014240026A1 (en) | 2015-08-20 |
| AU2014240026B2 true AU2014240026B2 (en) | 2018-06-14 |
Family
ID=51581684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014240026A Ceased AU2014240026B2 (en) | 2013-03-15 | 2014-03-14 | Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9815825B2 (enExample) |
| EP (1) | EP2970248B1 (enExample) |
| JP (1) | JP6514680B2 (enExample) |
| KR (1) | KR20150131309A (enExample) |
| CN (1) | CN105121437B (enExample) |
| AU (1) | AU2014240026B2 (enExample) |
| CA (1) | CA2903103C (enExample) |
| MX (1) | MX372775B (enExample) |
| WO (1) | WO2014152213A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012158913A2 (en) | 2011-05-17 | 2012-11-22 | Discoverybiomed Inc. | Treating protein folding disorders with small molecule cftr correctors |
| US9676779B2 (en) | 2012-11-20 | 2017-06-13 | Discoverybiomed, Inc. | Small molecule CFTR correctors |
| CA2891965A1 (en) | 2012-11-20 | 2014-05-30 | Discoverybiomed, Inc. | Small molecule bicyclic and tricyclic cftr correctors |
| CA2903103C (en) | 2013-03-15 | 2020-06-09 | Discoverybiomed, Inc. | Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders |
| HK1218537A1 (zh) | 2013-03-15 | 2017-02-24 | Discoverybiomed Inc. | 香豆素衍生物以及用於治疗过度增生性疾病的方法 |
| EP3157917B1 (en) | 2014-06-19 | 2020-03-18 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr activity |
| TW202140422A (zh) | 2014-10-06 | 2021-11-01 | 美商維泰克斯製藥公司 | 囊腫纖維化症跨膜傳導調節蛋白之調節劑 |
| MA41253A (fr) | 2014-12-23 | 2017-10-31 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
| WO2016105468A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| WO2016105477A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc | Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| US10548878B2 (en) | 2015-07-24 | 2020-02-04 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods of increasing CFTR activity |
| WO2017177124A1 (en) | 2016-04-07 | 2017-10-12 | Proteostasis Therapeutics, Inc. | Silicone atoms containing ivacaftor analogues |
| ES2954658T3 (es) | 2016-06-21 | 2023-11-23 | Proteostasis Therapeutics Inc | Compuestos, composiciones y procedimientos para aumentar la actividad de CFTR |
| CA3041676A1 (en) | 2016-10-26 | 2018-05-03 | Daniel Parks | Pyridazine derivatives, compositions and methods for modulating cftr |
| US20190248779A1 (en) | 2016-10-26 | 2019-08-15 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| EP3532461A1 (en) | 2016-10-26 | 2019-09-04 | Proteostasis Therapeutics, Inc. | N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis |
| CA3061476A1 (en) | 2017-04-28 | 2018-11-01 | Proteostasis Therapeutics, Inc. | 4-sulfonylaminocarbonylquinoline derivatives for increasing cftr activity |
| US20210369749A1 (en) | 2017-10-06 | 2021-12-02 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| WO2019136314A1 (en) | 2018-01-05 | 2019-07-11 | The Curators Of The University Of Missouri | Compounds and methods for treatment of cystic fibrosis |
| WO2020049189A1 (en) | 2018-09-09 | 2020-03-12 | Qanatpharma Gmbh | Use of cftr modulators for treating cerebrovascular conditions |
| CN110156761B (zh) * | 2019-06-18 | 2022-08-09 | 郑州大学 | 含香豆素-联苯骨架化合物、制备方法及其应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003066630A2 (en) * | 2002-02-07 | 2003-08-14 | Amgen Inc. | Quinolinone derivatives for treating cell proliferation related disorders |
| WO2012171954A1 (en) * | 2011-06-14 | 2012-12-20 | Azienda Ospedaliera Universitaria Integrata Di Verona | Trimethylangelicin as cftr corrector in bronchial epithelial cells |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5566580A (en) * | 1978-11-11 | 1980-05-20 | Kaken Pharmaceut Co Ltd | Coumarin derivative, its preparation and antiallergic agent containing the same as effective component |
| DE10133665A1 (de) * | 2001-07-11 | 2003-01-30 | Boehringer Ingelheim Pharma | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung |
| US20030055263A1 (en) * | 2001-07-11 | 2003-03-20 | Boehringer Ingelheim Pharma Kg | Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production |
| US20060122387A1 (en) | 2002-06-13 | 2006-06-08 | Cti Europe S.R.L. | Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells |
| CN101076332A (zh) * | 2004-10-13 | 2007-11-21 | Ptc医疗公司 | 吡唑或三唑化合物及其用于制备治疗体细胞突变相关疾病的药物的用途 |
| JP2008515992A (ja) | 2004-10-13 | 2008-05-15 | ピーティーシー セラピューティクス，インコーポレーテッド | 体細胞変異に起因する疾患の阻止／治療用医薬を製造するための規定化合物の使用 |
| US7799915B2 (en) | 2004-10-13 | 2010-09-21 | Wyeth Llc | Anilino-pyrimidine analogs |
| US20090012148A1 (en) * | 2005-11-01 | 2009-01-08 | Maxfield Frederick R | Reducing cellular cholesterol levels and/or treating or preventing phospholipidosis |
| CN101351208A (zh) * | 2005-11-01 | 2009-01-21 | 康乃尔研究基金会有限公司 | 减少细胞胆固醇水平和/或治疗或预防磷脂质病 |
| EP2581451B1 (en) | 2007-12-13 | 2016-03-09 | Indiana University Research and Technology Corporation | Compounds for inhibiting mammalian s-nitrosoglutathione reductase |
| US20120100609A1 (en) * | 2009-03-27 | 2012-04-26 | Crawford Brett E | N-linked glycan biosynthesis modulators |
| CA2903103C (en) | 2013-03-15 | 2020-06-09 | Discoverybiomed, Inc. | Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders |
| HK1218537A1 (zh) * | 2013-03-15 | 2017-02-24 | Discoverybiomed Inc. | 香豆素衍生物以及用於治疗过度增生性疾病的方法 |
-
2014
- 2014-03-14 CA CA2903103A patent/CA2903103C/en active Active
- 2014-03-14 CN CN201480009649.8A patent/CN105121437B/zh not_active Expired - Fee Related
- 2014-03-14 EP EP14767955.9A patent/EP2970248B1/en not_active Not-in-force
- 2014-03-14 MX MX2015013173A patent/MX372775B/es active IP Right Grant
- 2014-03-14 US US14/775,010 patent/US9815825B2/en not_active Expired - Fee Related
- 2014-03-14 KR KR1020157029643A patent/KR20150131309A/ko not_active Ceased
- 2014-03-14 AU AU2014240026A patent/AU2014240026B2/en not_active Ceased
- 2014-03-14 WO PCT/US2014/027079 patent/WO2014152213A2/en not_active Ceased
- 2014-03-14 JP JP2016502329A patent/JP6514680B2/ja not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003066630A2 (en) * | 2002-02-07 | 2003-08-14 | Amgen Inc. | Quinolinone derivatives for treating cell proliferation related disorders |
| WO2012171954A1 (en) * | 2011-06-14 | 2012-12-20 | Azienda Ospedaliera Universitaria Integrata Di Verona | Trimethylangelicin as cftr corrector in bronchial epithelial cells |
Non-Patent Citations (17)
| Title |
|---|
| CAS Registry Number 312703-21-2; STN entry date 04 Jan 2001; Chemical Name: 2H-1-Benzopyran-2-one, 8-methoxy-3-[2-[[3-(trifluoromethyl)phenyl]amino]-4-thiazolyl]- * |
| CAS Registry Number 313954-55-1; STN entry date 15 Jan 2001; Chemical Name: 2H-1-Benzopyran-2-one, 7-methoxy-3-[2-(phenylamino)-4-thiazolyl]- * |
| CAS Registry Number 313954-56-2; STN entry date 15 Jan 2001; Chemical Name: 2H-1-Benzopyran-2-one, 8-methoxy-3-[2-(phenylamino)-4-thiazolyl]- * |
| CAS Registry Number 325473-18-5; STN entry date 04 Mar 2001; Chemical Name: 2H-1-Benzopyran-2-one, 8-methoxy-3-[2-[(3-methylphenyl)amino]-4-thiazolyl]- * |
| CAS Registry Number 325804-06-6; STN entry date 06 Mar 2001; Chemical Name: 2H-1-Benzopyran-2-one, 8-methoxy-3-[2-[(2-methylphenyl)amino]-4-thiazolyl]- * |
| CAS Registry Number 325804-07-7; STN entry date 06 Mar 2001; Chemical Name: 2H-1-Benzopyran-2-one, 8-methoxy-3-[2-[(4-methylphenyl)amino]-4-thiazolyl]- * |
| CAS Registry Number 325804-09-9; STN entry date 06 Mar 2001; Chemical Name: 2H-1-Benzopyran-2-one, 8-methoxy-3-[2-[(2-methoxyphenyl)amino]-4-thiazolyl]- * |
| CAS Registry Number 364338-99-8; STN entry date 24 Oct 2001; Chemical Name: 2H-1-Benzopyran-2-one, 7-(diethylamino)-3-[2-[(2-methoxyphenyl)amino]-4-thiazolyl]- * |
| CAS Registry Number 403721-73-3; STN entry date 03 Apr 2002; Chemical Name: 2H-1-Benzopyran-2-one, 8-methoxy-3-[2-[[2-(trifluoromethyl)phenyl]amino]-4-thiazolyl]- * |
| CAS Registry Number 403721-74-4; STN entry date 03 Apr 2002; Chemical Name: 2H-1-Benzopyran-2-one, 8-methoxy-3-[2-[[4-(trifluoromethyl)phenyl]amino]-4-thiazolyl]- * |
| CAS Registry Number 724744-64-3; STN entry date 10 Aug 2004; Chemical Name: 2H-1-Benzopyran-2-one, 8-methoxy-3-[2-[(4-propoxyphenyl)amino]-4-thiazolyl]- * |
| HANMANTGAD, S. S. ET AL., "Biomimetic thiazolyl coumarins. National Academy", SCIENCE LETTERS, (1984), vol. 7, no. 3, pages 77 - 78 * |
| HONG YANG ET AL., "Stimulation of Airway and Intestinal Mucosal Secretion by Natural Coumarin CFTR Activators.", FRONTIERS IN PHARMACOLOGY, (2011), vol. 2, page 52 * |
| MORI, MATTIA ET AL., "A Combination Strategy to Inhibit Pim-1: Synergism between Noncompetitive and ATP-Competitive Inhibitors", CHEMMEDCHEM, (20130222), vol. 8, no. 3, pages 484 - 496 * |
| Panigrahi, CA75:129705 abstract only of J Indian Chem SOc, 48(7), 665-668, 1971. * |
| SRIMANTH, K. et al; 'Synthesis of some new types of thiazolyl coumarins', Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1999), 38B(4), 473-475 * |
| VENUGOPALA, K. N. ET AL., "Synthesis and evaluation of some substituted 2- arylamino coumarinyl thiazoles as potential NSAIDs.", ASIAN JOURNAL OF CHEMISTRY, (2004), vol. 16, no. 2, pages 872 - 876 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014152213A2 (en) | 2014-09-25 |
| CN105121437B (zh) | 2018-12-04 |
| JP6514680B2 (ja) | 2019-05-15 |
| CN105121437A (zh) | 2015-12-02 |
| EP2970248A4 (en) | 2017-01-11 |
| US9815825B2 (en) | 2017-11-14 |
| HK1218420A1 (en) | 2017-02-17 |
| MX2015013173A (es) | 2016-04-04 |
| CA2903103C (en) | 2020-06-09 |
| AU2014240026A1 (en) | 2015-08-20 |
| KR20150131309A (ko) | 2015-11-24 |
| CA2903103A1 (en) | 2014-09-25 |
| MX372775B (es) | 2020-06-29 |
| US20160024065A1 (en) | 2016-01-28 |
| EP2970248B1 (en) | 2020-04-22 |
| JP2016515131A (ja) | 2016-05-26 |
| WO2014152213A3 (en) | 2014-11-13 |
| EP2970248A2 (en) | 2016-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2970248B1 (en) | Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders | |
| US9676779B2 (en) | Small molecule CFTR correctors | |
| US9546176B2 (en) | Small molecule bicyclic and tricyclic CFTR correctors | |
| AU2014240003B2 (en) | Coumarin derivatives and methods of use in treating hyperproliferative diseases | |
| US9221840B2 (en) | Treating protein folding disorders with small molecule CFTR correctors | |
| US10494404B2 (en) | Quinolinium conjugates of cyclosporin | |
| CA3100335A1 (en) | Urolithin a and derivatives thereof for use in therapy | |
| JP2019513762A (ja) | 胆汁うっ滞及び線維症の処置方法 | |
| HK1218420B (en) | Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders | |
| US11746108B1 (en) | Triazolopyridine polymorph A | |
| US20250268979A1 (en) | Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |